Literature DB >> 1941818

Complications of immunosuppression associated with weekly low dose methotrexate.

J B Shiroky1, A Frost, J D Skelton, D G Haegert, M M Newkirk, C Neville.   

Abstract

Complications of immunosuppression are thought to be rare with the use of low dose pulse methotrexate (MTX) for nonneoplastic conditions. We describe 4 complications of immunosuppression observed in a group of 41 patients who had received MTX for at least 6 months, during a 2-year period. We report the first case of a reversible lymphoproliferative disorder similar to that reported with immunosuppressive therapy associated with organ transplantation. Two cases of disseminated herpes zoster and 1 case with Pneumocystis carinii pneumonia are described. As the indications for the use of low dose MTX broaden and older patients with other comorbid diseases are included, our experience suggests that complications of immunosuppression with prolonged use of MTX may be seen more commonly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941818

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

Review 1.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 2.  Methotrexate-related pulmonary complications in rheumatoid arthritis.

Authors:  P Barrera; R F Laan; P L van Riel; P N Dekhuijzen; A M Boerbooms; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

Review 3.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate.

Authors:  C Bologna; M C Picot; C Jorgensen; P Viu; R Verdier; J Sany
Journal:  Ann Rheum Dis       Date:  1997-02       Impact factor: 19.103

5.  Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.

Authors:  B Taillan; G Garnier; J Castanet; E Ferrari; A Pesce; P Dujardin
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

6.  Spontaneous remission of Epstein-Barr virus-negative non-Hodgkin's lymphoma after withdrawal of cyclosporine in a patient with refractory anemia.

Authors:  Masao Ogata; Hiroshi Kikuchi; Keiji Ono; Eiichi Ohtsuka; Ayako Gamachi; Kenji Kashima; Masaru Nasu
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 7.  Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

Authors:  E H Giannini; J T Cassidy
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 8.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature.

Authors:  Rita Rizzi; Paola Curci; Mario Delia; Erminia Rinaldi; Antonia Chiefa; Giorgina Specchia; Vincenzo Liso
Journal:  Med Oncol       Date:  2008-05-07       Impact factor: 3.064

Review 10.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.